Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq

• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1
• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1

Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r

• https://x.com/synovialjoints/status/2063240912851857742/photo/1

Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS

• https://x.com/synovialjoints/status/2063242046660358473/photo/1

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

Aiming for #DORIS #SLE #remission Or #LLDAS in #SLE Related to ⬆️survival #deep outcome in RCTs ➡️archived in #deucravacitinib ph2 #LTE & ph3 #dapirolizumab & #obintuzimab -achieved in #CAR-T trials in #lupus POS0683, 1364, 0695, OP0338 & several 🚗 T abst #EULAR2026 @RheumNow

JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR. BARI was effective vs. PBO in inducing & maintaining GC free rem. No new safety signals. New tx option for PMR (esp early). Decreases GC dependence & side effects. LB0005 @RheumNow #EULAR2026 https://t.co/mWrr1RdPCm

• https://x.com/RHEUMarampa/status/2063228962436743592/photo/1
• https://x.com/RHEUMarampa/status/2063228962436743592/photo/1
• https://x.com/RHEUMarampa/status/2063228962436743592/photo/1
• https://x.com/RHEUMarampa/status/2063228962436743592/photo/1

#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY

• https://x.com/DrMiniDey/status/2063166752268410881/photo/1

Key messages in the tx of ax/p-SpA: >csDMARDs only effective in pSpA >consider individualized treatment for bDMARDs and JAKis >Cycling TNFi equally effective to switching @RheumNow #EULAR2026 https://t.co/oeO3BxmYYo

• https://x.com/RHEUMarampa/status/2062911936103100779/photo/1

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA

Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288

+#RCT in #dermatomyositis with #brepocitinib Oral #TYK2/JAK1i 241 pts +outcomes #TIS total improvement score >40%TIS 68% v 44% #steroid tapering #skin improved rapidly #CLASI #OP0166 #POS0264 @RheumNow #EULAR2026 https://t.co/9WZl9RsXXe

• https://x.com/Janetbirdope/status/2062886558370296201/photo/1
• https://x.com/Janetbirdope/status/2062886558370296201/photo/1